Company Performance Metrics
Meriam Kabbaj: Co-founder, Chief Operations Officer, Chairman of the BoardPast Role: Celerion, Senior Manager, Clinical Pharmacology Sciences- Vincent Forster: CEOPast Role: ETH Zurich, Pioneer Fellow
Versantis is a Swiss pharmaceutical company developing medicines and diagnostics to revolutionize the care of patients with liver disease. Embracing lifesaving and preventive therapies, Versantis aims to answer the unmet medical need of millions of people worldwide.
Its lead candidate, VS-01, is currently at the preclinical stage and has the
potential to be the first drug for acute liver disease simultaneously supporting multiple failing organs. VS-01 targets 3 rare indications and received an Orphan Drug Designation in ALF. In addition, Versantis’ pipeline promises to improve patients’ outcomes in other medical fields; VS-02 and VS-03 are developed for chronic liver diseases and for the treatment of drug intoxications, both representing large market opportunities and significant upsides for Versantis.
Versantis was established in 2015 by Meriam Kabbaj in Zurich, Switzerland.
